Global Diabetic Neuropathy Market Size study, by Types of Disorder (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), and by Regional Forecasts 2018-2025

For discount/customization and buying a particular chapter, write to us at sales@bizwitresearch.com

Global Diabetic Neuropathy Market valued approximately USD 4680 million in 2016 is anticipated to grow with a healthy growth rate of more than 6.80% over the forecast period 2017-2025. The growth of this market primarily driven by the ever-growing pool of geriatric population with diabetes. The rise in availability of suitable treatment options and the growing awareness on PDN catalyzes the demand for PDN drugs. With only four drugs currently approved for the management of PDN (Lyrica, Cymbalta, Nucynta and Qutenza), there arises a huge opportunity for new and emerging market players with potential pipeline portfolio. Of the marketed products analyzed, Lyrica accounted for a maximum market share in 2017 and will continue similar trend through 2026.

The recent approval of Lyrica’s control release formulation in October 2017 further augments its market growth. The PDN drugs market observes a presence of strong pipeline portfolio, which would facilitate the overall growth during the forecast period from 2018 to 2026. Varoomed Co. Ltd.’s VM202 currently in phase III is the only gene therapy developed with disease modifying properties. However, the higher pricing of gene therapy could hamper the growth of VM202 in future. 

With diabetes being a global concern, PDN drugs market comprises a worldwide outreach. In 2017, North America dominated the market and expected to maintain its position throughout the forecast period. Availability of approved drugs and the presence of extensive diabetic patient pool contributed to the overall market growth. Asia Pacific exhibited fastest CAGR during the forecast period due to the growing awareness of PDN and the rise in healthcare expenditure.

Global Diabetic Neuropathy MarketThe objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type of Disorder:

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

By Regions:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
  • Asia Pacific
    • China
    • India
    • Japan
  • Latin America
    • Brazil
    • Mexico
  • Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2015, 2016

Base year – 2017

Forecast period – 2018 to 2025

The industry is seeming to be fairly competitive. Some of the leading market players include Pfizer, Inc, Johnson & Johnson, Boehringer Ingelheim GmbH., NeuroMetrix, Inc., Eli Lilly and Company, Astellas Pharma Inc, GlaxoSmithKline plc., Lupin Limited, Depomed, Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and so on. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Target Audience of the Global Diabetic Neuropathy Market in Market Study:

  • Key Consulting Companies & Advisors
  • Large, medium-sized, and small enterprises
  • Venture capitalists
  • Value-Added Resellers (VARs)
  • Third-party knowledge providers
  • Investment bankers
  • Investors

Chapter 1.           Global Diabetic Neuropathy Market Definition and Scope

1.1.         Research Objective

1.2.         Market Definition

1.3.         Scope of The Study

1.4.         Years Considered for The Study

1.5.         Currency Conversion Rates

1.6.         Report Limitation

Chapter 2.           Research Methodology

2.1.         Research Process

2.1.1.     Data Mining

2.1.2.     Analysis

2.1.3.     Market Estimation

2.1.4.     Validation

2.1.5.     Publishing

2.2.         Research Assumption

Chapter 3.           Executive Summary

3.1.         Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Billion)

3.2.         Key Trends

Chapter 4.           Global Diabetic Neuropathy Market Dynamics

4.1.         Growth Prospects

4.1.1.     Drivers

4.1.2.     Restraints

4.1.3.     Opportunities

4.2.         Industry Analysis

4.2.1.     Porter’s 5 Force Model

4.2.2.     PEST Analysis

4.2.3.     Value Chain Analysis

4.3.         Analyst Recommendation & Conclusion

Chapter 5.           Global Diabetic Neuropathy Market, By Type of  Disorder

5.1.         Market Snapshot

5.2.         Market Performance – Potential Model

5.3.         Global Diabetic Neuropathy Market, Sub Segment Analysis

5.3.1.     Peripheral Neuropathy

5.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)

5.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

5.3.2.     Autonomic Neuropathy

5.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)

5.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

5.3.3.     Proximal Neuropathy

5.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)

5.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

5.3.4.     Focal Neuropathy

5.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)

5.3.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

Chapter 6.           Global Diabetic Neuropathy Market, by Regional Analysis

6.1.         Diabetic Neuropathy Market, Regional Market Snapshot (2015-2025)

6.2.         North America Diabetic Neuropathy Market Snapshot

6.2.1.     U.S.

6.2.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.2.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.2.2.     Canada

6.2.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.2.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.3.         Europe Diabetic Neuropathy Market Snapshot

6.3.1.     U.K.

6.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.3.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.3.2.     Germany

6.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.3.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.3.3.     France

6.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.3.3.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.3.4.     Rest of Europe

6.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.3.4.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.4.         Asia Diabetic Neuropathy Market Snapshot

6.4.1.     China

6.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.4.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.4.2.     India

6.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.4.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.4.3.     Japan

6.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.4.3.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.4.4.     Rest of Asia Pacific

6.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.4.4.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.5.         Latin America Diabetic Neuropathy Market Snapshot

6.5.1.     Brazil

6.5.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.5.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.5.2.     Mexico

6.5.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.5.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.6.         Rest of The World

6.6.1.     South America

6.6.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.6.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

6.6.2.     Middle East and Africa

6.6.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)

6.6.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

Chapter 7.           Competitive Intelligence

7.1.         Company Market Share (Subject to Data Availability)

7.2.         Top Market Strategies

7.3.         Company Profiles

7.3.1.     Pfizer, Inc

7.3.1.1. Overview

7.3.1.2. Financial (Subject to Data Availability)

7.3.1.3. Product Summary

7.3.1.4. Recent Developments

7.3.2.     Johnson & Johnson

7.3.3.     Boehringer Ingelheim GmbH.

7.3.4.     NeuroMetrix, Inc.

7.3.5.     Eli Lilly and Company

7.3.6.     Astellas Pharma Inc

7.3.7.     GlaxoSmithKline plc.

7.3.8.     Lupin Limited

7.3.9.     Depomed, Inc.

7.3.10.   Glenmark Pharmaceuticals Ltd.

7.3.11.   Arbor Pharmaceuticals, LLC

The research for Global Diabetic Neuropathy Market focuses deeply on the entire value chain of the market. However, the market size estimates are purely based on the consumer side of the value chain wherein the market sizes have been calculated by analyzing the average demand for Third Party Logistics (3PL) across various applications.

The revenue for Global Diabetic Neuropathy Market is calculated as sum market sizes of different segments such as Types of Disorder and regions. Further, some other key data points considered to calculate the revenue for Global Diabetic Neuropathy Market includes:

  • Revenues from key companies
  • Key company market share analysis
  • Consumer spending analysis
  • Regional export and import analysis
  • Sales revenue generated by various applications in different geographies

An extensive primary and secondary research has been conducted on key industry people, through questionnaires, telephonic conversations, email conversations, and interviews to verify the market estimations. Various government websites/portals and paid data sources are considered as a key source of secondary research.

We utilize a combination of bottom-up & top-down methodology for market estimations & forecasts. Additionally, we employ data triangulation techniques to verify each of the market estimates and forecasts through primary interviews and feedbacks.

All the estimates are derived from simulation models which is our proprietary technique. Each of these models is different from each other are a combination of correlation, regression and time series analysis. Each of these models is basically divided into two types namely economic and technological. Economical models are used to determine short-term market estimates and technological models are used for long-term estimates & forecasts.  


We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.

Buy Now


Single User – $3,950

Enterprise License – $5,550

Loading…